Rivaroxaban For Suspension shortage
To Be Discontinued 1 presentations · 1 manufacturers · first FDA posting 2026-09-18 · last update 2026-09-18
Manufacturers: Janssen Pharmaceuticals
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Xarelto, For Suspension, 155 mg (NDC 50458-575-01) | Janssen Pharmaceuticals | To Be Discontinued | — | Business Decision | Posted 09/18/2026 Updated 09/18/2026 Discontinued 09/18/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)